Harvard Apparatus Regenerative Technology (HRGN)
OTHER OTC:HRGN
Want to see HRGN full AI Analyst Report?
HRGN Stock Chart & Stats
$1.82
$0.07(2.66%)
At close: 4:00 PM EST
$1.82
$0.07(2.66%)
Day’s Range― - ―
52-Week Range$0.94 - $2.22
Previous CloseN/A
Volume1.21K
Average Volume (3M)1.13K
Market Cap
$20.92M
Enterprise Value$20.68M
Total Cash (Recent Filing)$419.00K
Total Debt (Recent Filing)$173.00K
Price to Earnings (P/E)―
Beta-0.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,580,744
10 Day Avg. Volume797
30 Day Avg. Volume1,125
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)28.75
Price to Sales (P/S)43.17
P/FCF Ratio-7.94
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue94.41
Enterprise Value/Gross Profit-55.28
Enterprise Value/Ebitda-3.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Milestone: First Patient TreatedTreating the first patient in a regulated Phase 1 esophageal implant trial materially de‑risks the program and establishes operational proof of concept. This milestone enhances long‑term clinical credibility, supports future enrollment and funding discussions, and strengthens the path toward regulatory data readouts and commercialization.
Strategic Clinical PartnershipsEstablished collaborations with Mayo Clinic and IQVIA provide durable execution capability: clinical site access, trial management, and data quality. These partnerships reduce operational risk, improve trial logistics and patient recruitment, and increase the likelihood of reliable clinical evidence and downstream commercialization support.
Management Backstop Via Insider FinancingThe CEO’s bridge financing signals management commitment and short‑term liquidity support, which can sustain clinical progress without immediate market issuance. This alignment can preserve program continuity, enabling the company to reach value creating milestones that increase access to larger rounds or strategic partners.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$4.0M TTM) means the business cannot self‑fund operations or trials. Over the next several months the company will remain dependent on external capital; continued cash burn raises dilution risk and could interrupt clinical progress if additional funding is delayed or costly.
Minimal Revenue & Heavy LossesExtremely low product or service revenue combined with large negative gross and net margins indicates the company is not generating operating income. This structural lack of revenue undermines business sustainability absent successful commercialization or recurring non‑dilutive funding, increasing long‑term financing pressure.
Eroded Equity & Balance Sheet FragilityA sharply reduced equity cushion (to ~$0.09M TTM) and elevated debt‑to‑equity magnify solvency risk and limit financial flexibility. With few tangible assets and contracting capital base, the company is vulnerable to funding shocks and faces weaker negotiating leverage with investors or partners, raising structural risk.
Harvard Apparatus Regenerative Technology News
HRGN FAQ
What was Harvard Apparatus Regenerative Technology’s price range in the past 12 months?
Harvard Apparatus Regenerative Technology lowest stock price was $0.94 and its highest was $2.22 in the past 12 months.
What is Harvard Apparatus Regenerative Technology’s market cap?
Harvard Apparatus Regenerative Technology’s market cap is $20.92M.
When is Harvard Apparatus Regenerative Technology’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Harvard Apparatus Regenerative Technology’s earnings last quarter?
Currently, no data Available
Is Harvard Apparatus Regenerative Technology overvalued?
According to Wall Street analysts Harvard Apparatus Regenerative Technology’s price is currently Overvalued.
Does Harvard Apparatus Regenerative Technology pay dividends?
Harvard Apparatus Regenerative Technology does not currently pay dividends.
What is Harvard Apparatus Regenerative Technology’s EPS estimate?
Harvard Apparatus Regenerative Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Harvard Apparatus Regenerative Technology have?
Harvard Apparatus Regenerative Technology has 17,580,744 shares outstanding.
What happened to Harvard Apparatus Regenerative Technology’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Harvard Apparatus Regenerative Technology?
Currently, no hedge funds are holding shares in HRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. It also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Moleculin Biotech
―
Pulmatrix
―
SAB Biotherapeutics
―
Longeveron
―
Ownership Overview
Options Prices
Currently, No data available
---